3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Muscle Invasive Bladder Cancer
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Disease
1
Advanced Solid Malignancies
1
Advanced Metastatic Breast Cancer
1
Advanced Cancer
1
Interventions
Cyclophosphamide
61
Rituximab
60
Etoposide
28
fludarabine phosphate
23
Prednisone
23
fludarabine
22
Vincristine
19
Filgrastim
19
Doxorubicin
19
ibrutinib
16
Peripheral Blood Stem Cell Transplantation
16
venetoclax
15
Lenalidomide
14
Bortezomib
14
Carboplatin
13
CT-P10
13
Gemcitabine
12
Vorinostat
11
Cytarabine
11
pembrolizumab
9
Radiotherapy
9
Melphalan
9
Magnetic Resonance Spectroscopy
9
Dexamethasone
9
Bendamustine Hydrochloride
9
Paclitaxel
8
Ifosfamide
8
Cyclosporine
8
Biopsy
8
Tacrolimus
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma, Large B-Cell, Diffuse
×
vistusertib
×
Clear all
NCT02780830
2016-09-15
INHIBITOR
AstraZeneca
Phase 1
Withdrawn